Answers are grounded in this paper and cite their sources.
This editorial highlights a persistent gender gap in secondary cardiovascular prevention, emphasizing that women with coronary heart disease continue to have worse risk factor control than men.
This editorial refers to ‘Gender gap in risk factor control of coronary patients far from closing: results from the European Society of Cardiology EUROASPIRE V Registry’ by P. Vynckier et al., pp. 344–351. Cardiovascular disease (CVD) has been traditionally considered a male disease, and for many years it has been under-estimated and under-recognized in women. Nevertheless, as recently reaffirmed by Vynckier et al.,1 CVD remains the leading cause of mortality and morbidity across Europe, with about 47% of women and 39% of men dying from CVD. Despite several evidences on the major benefits of the management of modifiable risk factors (RFs) in subjects with established coronary heart disease (CHD), an unacceptably high rate of patients at high CVD risk fails to achieve lifestyle, blood pressure, lipid, and glycaemic recommended targets as defined in the 2016 ESC guidelines on CVD prevention in clinical practice.2 Several studies in Western populations have suggested that the secondary prevention control of cardiovascular RFs is generally even lower in women than in men, despite gender-neutral recommendations. Results from EUROASPIRE III,3 IV,4 and V5 found similar rates, showing substantial gender differences in the control of RFs in patients with CHD, with women having an overall worse RFs control compared to men (Table 1). RFs control of CHD patients according to EUROASPIRE III, IV, V. -Women less likely to achieve target lipid and HbA1c levels -Women had a higher prevalence of obesity -Less use of cardioprotective drugs -BP control worse among women than men (This gap did not appear to narrow between 1994 and 2007) -Women less likely to achieve target lipid and HbA1c levels -BP control worse among women than men -Women had a higher prevalence of obesity and were less likely to reach adequate levels of physical activity -Less use of cardioprotective drugs -Largest sex differences were seen among elderly patients and among those with lower levels of education. - Women less likely to achieve target lipid and HbA1c level -Women more likely to be non-smoker (significant gender by country income interaction effect) -Women had a higher prevalence of obesity (significant gender by country income interaction effect) and were less likely to reach recommended levels of physical activity - No gender differences observed in BP on target and women were more likely than men to use anti-hypertensive medications The Sixth Joint European Society guidelines (2016)2 were used to define the RFs targets: -Current smoking was defined as self-reported smoking and/or a breath carbon monoxide > 10 ppm. Smoking cessation was defined as non-smoking at time of the interview among those who smoked in the month before the recruiting event. -A recommended level of physical activity was defined as regularly physical activity for at least 30 min, 5 times or more a week. -Obesity was defined as a body mass index (BMI) ≥ 30 kg/m2 -Targets for blood pressure (BP) were set at <140/90 mmHg and <140/85 mmHg in patients with diabetes. ‘Controlled hypertension’ was used to indicate BP levels on target in patients treated with anti-hypertensive medication. -Target lipid level was defined as a LDL-C < 1.8 mmol/L. -HbA1c level targets were defined as <7% in patients with self-reported diabetes and <6.5% in patients without diabetes. -Women less likely to achieve target lipid and HbA1c levels -Women had a higher prevalence of obesity -Less use of cardioprotective drugs -BP control worse among women than men (This gap did not appear to narrow between 1994 and 2007) -Women less likely to achieve target lipid and HbA1c levels -BP control worse among women than men -Women had a higher prevalence of obesity and were less likely to reach adequate levels of physical activity -Less use of cardioprotective drugs -Largest sex differences were seen among elderly patients and among those with lower levels of education. - Women less likely to achieve target lipid and HbA1c level -Women more likely to be non-smoker (significant gender by country income interaction effect) -Women had a higher prevalence of obesity (significant gender by country income interaction effect) and were less likely to reach recommended levels of physical activity - No gender differences observed in BP on target and women were more likely than men to use anti-hypertensive medications The Sixth Joint European Society guidelines (2016)2 were used to define the RFs targets: -Current smoking was defined as self-reported smoking and/or a breath carbon monoxide > 10 ppm. Smoking cessation was defined as non-smoking at time of the interview among those who smoked in the month before the recruiting event. -A recommended level of physical activity was defined as regularly physical activity for at least 30 min, 5 times or more a week. -Obesity was defined as a body mass index (BMI) ≥ 30 kg/m2 -Targets for blood pressure (BP) were set at <140/90 mmHg and <140/85 mmHg in patients with diabetes. ‘Controlled hypertension’ was used to indicate BP levels on target in patients treated with anti-hypertensive medication. -Target lipid level was defined as a LDL-C < 1.8 mmol/L. -HbA1c level targets were defined as <7% in patients with self-reported diabetes and <6.5% in patients without diabetes. RFs control of CHD patients according to EUROASPIRE III, IV, V. -Women less likely to achieve target lipid and HbA1c levels -Women had a higher prevalence of obesity -Less use of cardioprotective drugs -BP control worse among women than men (This gap did not appear to narrow between 1994 and 2007) -Women less likely to achieve target lipid and HbA1c levels -BP control worse among women than men -Women had a higher prevalence of obesity and were less likely to reach adequate levels of physical activity -Less use of cardioprotective drugs -Largest sex differences were seen among elderly patients and among those with lower levels of education. - Women less likely to achieve target lipid and HbA1c level -Women more likely to be non-smoker (significant gender by country income interaction effect) -Women had a higher prevalence of obesity (significant gender by country income interaction effect) and were less likely to reach recommended levels of physical activity - No gender differences observed in BP on target and women were more likely than men to use anti-hypertensive medications The Sixth Joint European Society guidelines (2016)2 were used to define the RFs targets: -Current smoking was defined as self-reported smoking and/or a breath carbon monoxide > 10 ppm. Smoking cessation was defined as non-smoking at time of the interview among those who smoked in the month before the recruiting event. -A recommended level of physical activity was defined as regularly physical activity for at least 30 min, 5 times or more a week. -Obesity was defined as a body mass index (BMI) ≥ 30 kg/m2 -Targets for blood pressure (BP) were set at <140/90 mmHg and <140/85 mmHg in patients with diabetes. ‘Controlled hypertension’ was used to indicate BP levels on target in patients treated with anti-hypertensive medication. -Target lipid level was defined as a LDL-C < 1.8 mmol/L. -HbA1c level targets were defined as <7% in patients with self-reported diabetes and <6.5% in patients without diabetes. -Women less likely to achieve target lipid and HbA1c levels -Women had a higher prevalence of obesity -Less use of cardioprotective drugs -BP control worse among women than men (This gap did not appear to narrow between 1994 and 2007) -Women less likely to achieve target lipid and HbA1c levels -BP control worse among women than men -Women had a higher prevalence of obesity and were less likely to reach adequate levels of physical activity -Less use of cardioprotective drugs -Largest sex differences were seen among elderly patients and among those with lower levels of education. - Women less likely to achieve target lipid and HbA1c level -Women more likely to be non-smoker (significant gender by country income interaction effect) -Women had a higher prevalence of obesity (significant gender by country income interaction effect) and were less likely to reach recommended levels of physical activity - No gender differences observed in BP on target and women were more likely than men to use anti-hypertensive medications The Sixth Joint European Society guidelines (2016)2 were used to define the RFs targets: -Current smoking was defined as self-reported smoking and/or a breath carbon monoxide > 10 ppm. Smoking cessation was defined as non-smoking at time of the interview among those who smoked in the month before the recruiting event. -A recommended level of physical activity was defined as regularly physical activity for at least 30 min, 5 times or more a week. -Obesity was defined as a body mass index (BMI) ≥ 30 kg/m2 -Targets for blood pressure (BP) were set at <140/90 mmHg and <140/85 mmHg in patients with diabetes. ‘Controlled hypertension’ was used to indicate BP levels on target in patients treated with anti-hypertensive medication. -Target lipid level was defined as a LDL-C < 1.8 mmol/L. -HbA1c level targets were defined as <7% in patients with self-reported diabetes and <6.5% in patients without diabetes. Vynckier et al. present an elegant and detailed analysis of the persistent gender gap in secondary cardiovascular prevention, based on the cross-sectional ESC EORP EUROASPIRE V (European Survey of Cardiovascular Disease Prevention And Diabetes) survey,5 conducted in 2016–2017, including data on 8261 CHD patients (25.8% women) across 27 European countries. This study was performed to identify RFs in CHD patients with and without diabetes, describing their management through lifestyle modifications and use of drug therapies in order to provide an objective assessment of the implementation of current evidence-based CVD prevention. The three EUROASPIRE Registries3–5 in an interval of about 15 years did not show substantial differences in the gender gap of the same specific RFs: lipid levels and glycated haemoglobin (HbA1c), obesity, and physical inactivity. An improvement in blood pressure control was found only in EUROSPIRE V, due to a more adherence to evidence-based drugs (Table 1). However, it is important to point out that a possible limitation in the comparison between EUROASPIRE III, IV, and V may be that the countries and centres participating in the three surveys were not exactly the same. Adding countries like Kazakhstan, Kyrgyzstan, and Egypt in the most recent survey could explain some of the trends, such as the improvement documented in the blood pressure control. In order to have a more coherent and reliable analysis of the data, perhaps, the comparisons should have been done only between countries and centres that participated in all three surveys. The strength of EUROASPIRE V, in comparison to previous studies, is the stratification of the analysis by country income level. This, in fact, revealed a significant gender by country income interaction effect for some RFs. In particular, stratification by country revealed a trend to significant gender differences for smoking behaviour in middle-income countries but not in high-income countries. A possible explanation, as reported by the authors, could be the increased smoking rates in female patients, especially in younger women, from high-income countries. Also, significant gender by country income interaction effect was found for being non-obese: women were generally less likely to be non-obese but in middle-income countries the odds of being non-obese is even lower in women compared to men. Then, the authors compare EUROASPIRE registries results, to VIRGO,6 SWEDEHEART,7 REACH,8 and SURF9 studies, that confirm a similar gender gap in RFs control. These studies derive from specific areas in and out of Europe and include a different method of enrolment, whereas another major strength of the EUROASPIRE surveys is that data are based on standardized methods and equipment, including central laboratory analyses. Why the persistent gap? The authors provide an interesting overview of the possible contributing causes of this risk profile gender gap (Figure 1). possible causes of gender gap in risk factors control of coronary heart disease patients. possible causes of gender gap in risk factors control of coronary heart disease patients. The authors clearly underline that one reason for the persistent gender gap in RFs control in secondary prevention may be the older age of onset of CHD in women. Women develop CHD on average 5–10 years later compared to men, partially explained by the loss of oestrogens protective effects after menopause. Developing CHD later in life may mean that women already have a worse cardiovascular risk profile, which may result in a greater effort needed to bring RFs on target. Furthermore, the lack of awareness among healthcare professionals and female patients concerning women’s risk for CHD, could contribute to explain the risk profile gender gap. In fact, the lack of awareness, with women less likely to be told by a healthcare professional that they are at risk for CHD, may account for less lifestyle modification that is the first step of prevention, which in turn contributes to physical inactivity and obesity (mostly central type) and, therefore, less achievement of target lipid and glycaemic (HbA1c) profile. Moreover, as pointed out by the authors, some ‘non-traditional’ RFs may contribute to the gender gap. The most important known traditional RFs affect both men and women, although the prevalence and the relative weight of each one is gender-specific. As underlined by authors, some RFs including smoking habit and diabetes may have an even more detrimental effect in female patients compared to men. Furthermore, when it comes to women’s primary and secondary prevention it is mandatory to know, recognize, and treat also emerging novel and unique to women RFs.10 These novel and unique to women RFs, partially mentioned by ESC,2 include obstetric conditions (pregnancy-related disorder) and non-obstetric conditions (including Polycystic Ovarian Syndrome, time onset of menarche, early menopause, breast artery calcification, breast cancer treatment, inflammatory and autoimmune diseases, and emotional stress disorders). As reported by the authors, in EUROASPIRE V women were more likely to have anxiety and depression. It has been widely demonstrated that chronic emotional stress is an increasingly recognized RF, both for direct biochemical pathways and for indirect mechanisms, as it is associated with less healthy behaviours (such as inadequate levels of physical activity and obesity), with a consequent worse metabolic profile (lipid and glycaemic level). Concerning the evidence that women were less likely to reach LDL-C target level, Vynckier et al. suggest several aspects that could contribute to this. First of all, there is only limited evidence about the effectiveness of evidence-based medications in women, as guidelines derived from clinical trials focused predominantly on male. Also, women were less likely to be treated with lipid-lowering medications and were less likely to adhere to statins because of more side effects. Looking at Table 1, it is easy to observe that (i) ESC recommendations did not fully reach the aim to promote evidence-based preventive cardiology, especially in the female population, suggesting the need for stronger strategies to improve the application of these recommendations and to reduce gender-inequalities in RFs control, (ii) the percentage of women interviewed remains very low, repeating the bias of low enrolment of women in randomized clinical trial on cardioprotective drugs, and (iii) the RFs control for secondary prevention still suboptimal over the years and it mostly takes into account the so-called ‘traditional’ RFs, perhaps underestimating the emerging RFs specific to women. In conclusion, despite several actions in order to reduce the CVD burden in women over the last years, the study by Vynckier et al. provides a further contemporary evidence of the inadequate RFs management for the secondary prevention of CHD especially in women, and that both patients and physicians continue to pay insufficient attention to lifestyle RFs which can unfavourably impact on the control of blood pressure, lipids, and diabetes. Thus, there is considerable potential to raise the standards of preventive cardiology, especially in female patients, that reach an even lower satisfactory secondary prevention than men. It is our opinion that one essential element to increase women’s awareness on cardiovascular risk should be trying to convince them that RFs promoting breast cancer, are the same as CHD, and fundamentally concern lifestyle, which is the priority recommendation of ESC Guidelines. The evidence of the reduction in breast cancer mortality is the most striking example, in fact, of how women's awareness can affect prevention. Conflict of interest: The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affi liations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Preventive Cardiology or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Lodi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: